Please login to the form below

Not currently logged in
Email:
Password:

New guidance for Valcyte

The US Food and Drug Administration has issued new guidance for the use of Roche's Valcyte in children following an organ transplant

The US Food and Drug Administration (FDA) has issued new dosing guidance for the use  of Roche's Valcyte (valganciclovir) in children and adolescents receiving a kidney or heart transplant.

The new guidance is designed to prevent drug overdosing in patients with a low body weight, low body surface area, and very low serum creatinine – a waste product produced by the body during energy production that is used to determine kidney function.

Low creatinine levels are common in patients who have poor muscle condition.

The FDA has advised patients using the medication to speak with their healthcare professional if they have questions regarding their prescription.

Healthcare professionals and patients are advised to report any adverse effects associated with the drug to the FDA's MedWatch Adverse Event Reporting programme.

Valcyte is used in post-operation patients between the ages of four months and 16 years who have undergone a kidney or heart transplant. It is effective in preventing cytomegalovirus (CMV) – a virus that can cause serious diseases, such as pneumonia, in people with weakened immune systems, including transplant patients.

16th September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....